vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and Udemy, Inc. (UDMY). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $194.0M, roughly 1.0× Udemy, Inc.). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs -1.2%, a 13.2% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs -3.0%). CORCEPT THERAPEUTICS INC produced more free cash flow last quarter ($38.4M vs $15.0M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs -0.7%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Udemy is a US-based education technology company. Founded as a massive open online course (MOOC) provider in 2010 by Eren Bali, Gagan Biyani, and Oktay Caglar; the company is based in San Francisco, California, with offices in the United States, Australia, India, Ireland, Mexico and Turkey. Its education platform allows both the creation and sharing of online courses. By early 2025, Udemy claimed to have millions of individual users. Courses are typically video-based and on-demand.

CORT vs UDMY — Head-to-Head

Bigger by revenue
CORT
CORT
1.0× larger
CORT
$202.1M
$194.0M
UDMY
Growing faster (revenue YoY)
CORT
CORT
+14.1% gap
CORT
11.1%
-3.0%
UDMY
Higher net margin
CORT
CORT
13.2% more per $
CORT
12.0%
-1.2%
UDMY
More free cash flow
CORT
CORT
$23.4M more FCF
CORT
$38.4M
$15.0M
UDMY
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
-0.7%
UDMY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CORT
CORT
UDMY
UDMY
Revenue
$202.1M
$194.0M
Net Profit
$24.3M
$-2.3M
Gross Margin
98.7%
66.0%
Operating Margin
2.2%
-1.8%
Net Margin
12.0%
-1.2%
Revenue YoY
11.1%
-3.0%
Net Profit YoY
-21.0%
76.4%
EPS (diluted)
$0.20
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
UDMY
UDMY
Q4 25
$202.1M
$194.0M
Q3 25
$207.6M
$195.7M
Q2 25
$194.4M
$199.9M
Q1 25
$157.2M
$200.3M
Q4 24
$181.9M
$199.9M
Q3 24
$182.5M
$195.4M
Q2 24
$163.8M
$194.4M
Q1 24
$146.8M
$196.8M
Net Profit
CORT
CORT
UDMY
UDMY
Q4 25
$24.3M
$-2.3M
Q3 25
$19.7M
$1.6M
Q2 25
$35.1M
$6.3M
Q1 25
$20.5M
$-1.8M
Q4 24
$30.7M
$-9.9M
Q3 24
$47.2M
$-25.3M
Q2 24
$35.5M
$-31.8M
Q1 24
$27.8M
$-18.3M
Gross Margin
CORT
CORT
UDMY
UDMY
Q4 25
98.7%
66.0%
Q3 25
97.8%
65.9%
Q2 25
98.2%
66.1%
Q1 25
98.5%
64.6%
Q4 24
98.4%
63.6%
Q3 24
98.4%
63.0%
Q2 24
98.5%
62.3%
Q1 24
98.3%
61.2%
Operating Margin
CORT
CORT
UDMY
UDMY
Q4 25
2.2%
-1.8%
Q3 25
4.9%
-0.1%
Q2 25
13.7%
2.0%
Q1 25
2.2%
-2.2%
Q4 24
13.9%
-5.8%
Q3 24
25.5%
-15.1%
Q2 24
21.7%
-13.1%
Q1 24
20.1%
-11.5%
Net Margin
CORT
CORT
UDMY
UDMY
Q4 25
12.0%
-1.2%
Q3 25
9.5%
0.8%
Q2 25
18.1%
3.1%
Q1 25
13.1%
-0.9%
Q4 24
16.9%
-4.9%
Q3 24
25.9%
-12.9%
Q2 24
21.7%
-16.4%
Q1 24
18.9%
-9.3%
EPS (diluted)
CORT
CORT
UDMY
UDMY
Q4 25
$0.20
$-0.01
Q3 25
$0.16
$0.01
Q2 25
$0.29
$0.04
Q1 25
$0.17
$-0.01
Q4 24
$0.25
$-0.06
Q3 24
$0.41
$-0.17
Q2 24
$0.32
$-0.21
Q1 24
$0.25
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
UDMY
UDMY
Cash + ST InvestmentsLiquidity on hand
$372.2M
$358.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$647.8M
$210.5M
Total Assets
$836.7M
$617.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
UDMY
UDMY
Q4 25
$372.2M
$358.7M
Q3 25
$421.7M
$371.2M
Q2 25
$342.2M
$392.0M
Q1 25
$322.8M
$357.0M
Q4 24
$383.3M
$354.4M
Q3 24
$380.3M
$357.1M
Q2 24
$473.2M
$420.9M
Q1 24
$410.8M
$430.7M
Stockholders' Equity
CORT
CORT
UDMY
UDMY
Q4 25
$647.8M
$210.5M
Q3 25
$631.9M
$221.8M
Q2 25
$635.8M
$233.4M
Q1 25
$683.3M
$209.4M
Q4 24
$679.6M
$197.4M
Q3 24
$638.8M
$196.3M
Q2 24
$596.2M
$252.3M
Q1 24
$547.9M
$296.5M
Total Assets
CORT
CORT
UDMY
UDMY
Q4 25
$836.7M
$617.7M
Q3 25
$823.6M
$618.9M
Q2 25
$801.7M
$644.0M
Q1 25
$846.5M
$639.0M
Q4 24
$840.6M
$605.6M
Q3 24
$784.3M
$608.9M
Q2 24
$714.6M
$671.9M
Q1 24
$655.9M
$708.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
UDMY
UDMY
Operating Cash FlowLast quarter
$38.4M
$15.5M
Free Cash FlowOCF − Capex
$38.4M
$15.0M
FCF MarginFCF / Revenue
19.0%
7.7%
Capex IntensityCapex / Revenue
0.0%
0.3%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters
$81.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
UDMY
UDMY
Q4 25
$38.4M
$15.5M
Q3 25
$54.5M
$15.7M
Q2 25
$43.9M
$44.2M
Q1 25
$5.1M
$12.2M
Q4 24
$59.3M
$9.6M
Q3 24
$73.8M
$-6.1M
Q2 24
$41.2M
$28.6M
Q1 24
$23.8M
$21.0M
Free Cash Flow
CORT
CORT
UDMY
UDMY
Q4 25
$38.4M
$15.0M
Q3 25
$15.1M
Q2 25
$43.9M
$41.9M
Q1 25
$5.0M
$9.8M
Q4 24
$59.2M
$8.4M
Q3 24
$72.2M
$-6.7M
Q2 24
$40.8M
$28.2M
Q1 24
$20.8M
FCF Margin
CORT
CORT
UDMY
UDMY
Q4 25
19.0%
7.7%
Q3 25
7.7%
Q2 25
22.6%
21.0%
Q1 25
3.2%
4.9%
Q4 24
32.5%
4.2%
Q3 24
39.5%
-3.4%
Q2 24
24.9%
14.5%
Q1 24
10.6%
Capex Intensity
CORT
CORT
UDMY
UDMY
Q4 25
0.0%
0.3%
Q3 25
0.0%
0.3%
Q2 25
0.0%
1.1%
Q1 25
0.1%
1.2%
Q4 24
0.1%
0.6%
Q3 24
0.9%
0.3%
Q2 24
0.3%
0.2%
Q1 24
0.0%
0.1%
Cash Conversion
CORT
CORT
UDMY
UDMY
Q4 25
1.58×
Q3 25
2.77×
9.58×
Q2 25
1.25×
7.06×
Q1 25
0.25×
Q4 24
1.93×
Q3 24
1.56×
Q2 24
1.16×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons